Literature DB >> 15988577

Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.

X Palomer, L Calpe-Berdiel, J Verdaguer, J Carrillo, X Pastor, D Mauricio, F Blanco-Vaca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15988577     DOI： 10.1007/s00125-005-1834-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  11 in total

Review 1.  Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

Authors:  S I McFarlane; R Muniyappa; R Francisco; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

Review 2.  Anti-inflammatory and immunomodulatory effects of statins.

Authors:  Luis Miguel Blanco-Colio; José Tuñón; Jose Luis Martín-Ventura; Jesús Egido
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

4.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

Authors:  G Paolisso; M Barbagallo; G Petrella; E Ragno; M Barbieri; M Giordano; M Varricchio
Journal:  Atherosclerosis       Date:  2000-05       Impact factor: 5.162

5.  Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.

Authors:  K C B Tan; W S Chow; S C F Tam; V H G Ai; C H L Lam; K S L Lam
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

6.  A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice.

Authors:  Silvia Gregori; Nadia Giarratana; Simona Smiroldo; Milan Uskokovic; Luciano Adorini
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

Review 7.  Statins: the new aspirin?

Authors:  N R Veillard; F Mach
Journal:  Cell Mol Life Sci       Date:  2002-11       Impact factor: 9.261

8.  A novel anti-inflammatory role for simvastatin in inflammatory arthritis.

Authors:  Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Authors:  David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.

Authors:  Makoto Kanda; Kumi Satoh; Kazuo Ichihara
Journal:  Biol Pharm Bull       Date:  2003-12       Impact factor: 2.233
View more
  3 in total

1.  Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.

Authors:  Kareem L Graham; Lowen Y Lee; John P Higgins; Lawrence Steinman; Paul J Utz; Peggy P Ho
Journal:  Arthritis Rheum       Date:  2008-07

2.  Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.

Authors:  Stephan Martin; Christian Herder; Nanette C Schloot; Wolfgang Koenig; Tim Heise; Lutz Heinemann; Hubert Kolb
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

3.  Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).

Authors:  Alexander Strom; Hubert Kolb; Stephan Martin; Christian Herder; Marie-Christine Simon; Wolfgang Koenig; Tim Heise; Lutz Heinemann; Michael Roden; Nanette C Schloot
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.